Methodological aspects of lung cancer clinical trials in the era of targeted agents.
about
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewWhich Metrics Are Appropriate to Describe the Value of New Cancer Therapies?Gefitinib in non small cell lung cancerZEPHYR: failure of a "spring wind" in lung cancer.Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancer.Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer.Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.
P2860
Q26766584-C1F05E2B-20BE-44E4-AC52-6187AB0DE48DQ26858853-284FADC9-E797-409E-B45B-714AF87BFC7FQ35031807-E601FFA6-CE15-4A25-A20A-28FADA58744DQ35200470-A3268A4D-9749-4703-BB6A-92658746A9ECQ36594253-93BD0505-F241-4772-93E0-DE1D02FA4655Q37731264-F6DF836D-E1A3-4DAD-8120-1C486D6F5DDBQ38148583-C2A589B8-F0FA-485C-9DE9-B941A75C7D41Q38389980-1AE5A846-7EBA-42AC-97E4-C867548C7F92Q38723404-DCA46B95-A753-4EFE-B5FC-1DF2CC0F437DQ46255750-98F7C660-62DA-4F6D-8537-CC3998D4DE88Q55054705-96A7DE71-D7E8-4CC6-80EF-6020B82BBF27
P2860
Methodological aspects of lung cancer clinical trials in the era of targeted agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Methodological aspects of lung cancer clinical trials in the era of targeted agents.
@en
Methodological aspects of lung cancer clinical trials in the era of targeted agents.
@nl
type
label
Methodological aspects of lung cancer clinical trials in the era of targeted agents.
@en
Methodological aspects of lung cancer clinical trials in the era of targeted agents.
@nl
prefLabel
Methodological aspects of lung cancer clinical trials in the era of targeted agents.
@en
Methodological aspects of lung cancer clinical trials in the era of targeted agents.
@nl
P2093
P50
P1433
P1476
Methodological aspects of lung cancer clinical trials in the era of targeted agents.
@en
P2093
Ciro Gallo
Ermelinda De Maio
Francesco Perrone
Massimo Di Maio
P304
P356
10.1016/J.LUNGCAN.2009.10.001
P577
2009-10-28T00:00:00Z